EUnetHTA 21 – Stakeholder Meeting

13 July 2022 14:00-16:00 CET





European Network for Health Technology Assessment | EUnetHTA 21 | www.eunethta.eu

1. Welcome from the Chair of the Consortium Executive Board (CEB) and objective of the meeting

Niklas Hedberg, TLV



Upcoming stakeholder meetings

Meeting date	Objective
July 2022	EMA/EUnetHTA 21 bilateral in accordance to work plan
October 2022	EMA/EUnetHTA 21 bilateral in accordance to work plan
18 November 2022	4 th General EUnetHTA 21 Stakeholder Meeting
February 2022	EMA/EUnetHTA 21 bilateral in accordance to work plan
12 May 2023	5 th General EUnetHTA 21 Stakeholder Meeting
8 September 2023	6th & final General EUnetHTA 21 Stakeholder Meeting
September/October 2023	EMA/EUnetHTA 21 bilateral in accordance to work plan

Housekeeping of today's meeting

Alzbeta Tuckova, ZIN



Information for attendees

Entering the meeting:

- Please ensure you have logged in with your name, surname, organisation and country *i.e.* Merle Tenberg (ZIN, The Netherlands).
- You can rename yourself after you have logged in.
- Please do not switch your webcam on.



Information for attendees

Questions:

- To ask questions, you may:
 - Post them in the chat or raise your hand during the dedicate timeslot (at the end of relevant presentations or during the Q&A item).
- Responses to all questions will be coordinated by the Chair and will be taken at the end of relevant item.
- Please note: for internal purposes this meeting will be recorded.



Information for attendees

Technical issues:

- If you experience problems with Zoom during the meeting, please:
 - 1. Go to <u>www.zoom.com</u> and search for help.
 - 2. Contact <u>euenthta@zinl.nl</u> or call Merle Tenberg on

+31 6 51 06 80 53 for support (You may wish to take a picture of these contact details).



Today's agenda

Niklas Hedberg, TLV



Agenda

ID	Time	Description	Presenter/s
#1	14:00-14:10	Welcome from the Chair of the Consortium Executive Board (CEB) and objective of the meeting	Niklas Hedberg, TLV
#2	14:10-14:20	Update from the European Commission	Julia Schmitz, EC Valentina Barbuto, EC
#3	14:20 -14:45	 Update on status of deliverables a) Joint Scientific Consultations b) Joint Clinical Assessments c) Transversal Activities 	Chantal Guilhaume, HAS Antje Behring, G-BA
#4	14:45-15:15	Content a) D7.1 HTD interaction b) D7.2/7.3 Patient/HCP	Anne Willemsen, ZIN Maggie Galbraith, HAS
#5	15:15-15:30	JCA pilot a) Objectives b) National uptake c) Template d) Timelines	Chantal Guilhaume, HAS Anne Willemsen, ZIN
#6	15:30-15:50	Q&A	Niklas Hedberg, TLV
#7	15:50-16:00	Closing remarks	Niklas Hedberg, TLV

2. Update from the European Commission

Julia Schmitz, EC Valentina Barbuto, EC





Implementation of the Regulation (EU) 2021/2282 on Health Technology Assessment

Valentina BARBUTO and Julia SCHMITZ Policy officers, Unit B6, DG SANTE

EUnetHTA21 Stakeholder Meeting, 13 July 2022

EC conference on HTA Regulation (22 June 2022)



https://health.ec.europa.eu/events/conference-new-regulationhealth-technology-assessment-hta-2022-06-22_en

Presentations

<u>The implementation rolling plan – What's next</u> (EN Ieee) Flora Giorgio European Commission - DG Health and Food Safety

EUnetHTA 21 - Supporting the future of European HTA cooperation (EN International Marcus Guardian National Health Care Institute (ZIN, The Netherlands)

<u>Joint HTA on medical devices – Looking ahead</u> (EN I + • • • Rosanna Tarricone Bocconi University

Patients and healthcare professionals as external experts in HTA (EN I even) François Houÿez EURORDIS

Advancing HTA methodology for joint work: Joint Scientific Consultations (EN I and Antje Behring


Federal Joint Committee (G-BA, Germany)

Advancing HTA methodology for joint work: Joint Clinical Assessments (EN Inc.

Chantal Guilhaume National Authority for Health (HAS, France)



HTA Regulation MS Coordination Group on HTA



MP = medicinal products, MD = medical devices



EC HTA implementation website

Implementation rolling plan The rolling plan below contains a list of key activities that the European Commission has carried out or intends to carry out in preparation for the implementation of Regulation (EU) 2021/2282. The plan is subject to regular review in order to provide national authorities, health technology developers and stakeholders with the most updated information. Rolling plan (et) ----) Member State Coordination Group on HTA (HTACG) The HTAR established the Coordination Group on Health Technology Assessment (the (HTACG) (minute composed of Member States' representatives, mainly from HTA authorities and bodies Latest updates News announcement | 27 June 2022 News announcement | 20 June 2022 Flash report - Member State Live web streaming - Conference Coordination Group on HTA (HTACG) "The Regulation on health technology assessment - What's next" (22 June (21 June 2022) 2022)


https://health.ec.europa.eu/health-technology-assessment/regulation-health-technology-assessment/implementation-regulation-health-technology-assessment_en



HTA Regulation Implementation timeline

Adoption

December 2021





Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the <u>CC BY 4.0</u> license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: element concerned, source: e.g. Fotolia.com; Slide xx: element concerned, source: e.g. iStock.com



3. Update on status of deliverables

Antje Behring, G-BA Chantal Guilhaume, HAS




3a. Joint Scientific Consultations

Antje Behring, G-BA



History and future of HTA advice

- From the beginning in collaboration with EMA
- EUnetHTA (21) project phase → Continuation via HTA Regulation (HTAR)





JSC in EUnetHTA 21

- Last project phase before continuation within the framework of HTAR
- > HTA will remain a relevant topic for the future
- Parallel EMA/EUnetHTA 21 JSCs: consultations together with EMA
- According to EUnetHTA 21 service contract: max. 8 JSCs planned
- 1st Open Call: 3 candidates accepted (selection criteria)
 - 1 JSC already completed, 2 ongoing
 - Indications: oncology, orphan drugs
- 2nd Open Call open now: from June 6th to August 31st 2022
 - 5 JSCs are planned
- New guidance for patient and HCP involvement currently under revision
 - Public consultation: 1-30 August 2022




Expert involvement in JSC

Expert involvement JSC

Purpose	Involvement type	Level	Method(s)	Information provided to the expert
 Obtain information on living with the disease/expertis e with the treatment of the disease and expectations of new treatment; 	External expert	National , generally	Approach 1: Interview (or written statement) based on questionnaire	No documents are shared
	External expert	National , generally	Approach 2: Approach 1 + Respond to specific questions re: HTD development plan	Providing the briefing package or relevant sections of the briefing package when a specific contribution is required
 Getting input following the PICO scheme 	External expert	European	Approach 3: Approach 2 + Review draft List of Issues and participate in meeting with EMA and HTD	



JSC key steps and expert identification / involvement – European level



Expenses to contribute in JSC as expert

- EUnetHTA 21 DOI and ECA form have to be filled in
 - Central approval by Conflict of Interest Committee

National level expert:

- Interview (or written statement) based on questionnaire
 - > Questionnaire shared beforehand
 - Duration 30-60min, validation of minutes
 - Written feedback mostly preferred by HCPs

European level expert (recruited by JSC Secretariat, member of European patient organisation):

- Interview (or written statement) based on questionnaire
- Review draft List of Issues feedback optional, 30min?
- Participate in meeting with EMA and HTD 3 hours



Expert recruitment for JSC

- Expert recruitment within tight timelines
- If you are contacted by the JSC Secretariat or one of our HTA partners, please respond in a timely manner
- Challenges of expert recruitment patients and HCPs: collaboration of JSC Secretariat with other HTABs of the JSC HOGs and also EMA to find experts
- At the moment we are in the process of building a functional network of contacts: sources, e.g. EUnetHTA 21 stakeholder pool, EMA eligible patient organisations etc.
- Differences in EMA vs. EUnetHTA 21 COI policy!

Your help and support upon initial contact is much appreciated! Thank you in advance!

You are kindly invited to raise questions now or send them anytime to the EUnetHTA 21 JSC Secretariat: <u>EUnetHTA21-JSC@g-ba.de</u>



3b. Joint Clinical Assessments

Chantal Guilhaume, HAS



EUnetHTA 21 Joint Clinical Assessment Deliverables

Deliverables	Start Public consultation
JCA PRODUCTIONS	2023
METHODOLOGICALGUIDELINES	
D4.2.1 Scoping process	Closed
D4.3.1/D4.3.2 Direct and Indirect Comparisons	Closed/August 2022
D4.4.1 Endpoints	October 3rd 2022
D4.5.1 Applicability of evidence	Ongoing
D4.6.1 Validity of clinical studies	Ongoing
D4.7.2. Assessment of High risk MD and IVD	Closed
• D4.7.3 + 4.7.4 EUDAMED Reporting template, Guidance for EUDAMED	Closed
TEMPLATES	
D5.1. Submission Dossier Template	Ongoing
D5.2.1.JCAReport Template	Aug 1st 2022
PROCEDURALGUIDELINES	
• D5.3.1 Selection criteria for assessor and co-assessor	Closed
D5.3.2 HTAb Technical Expert Working Group	Closed 28

3c. Transversal Activities

Chantal Guilhaume, HAS



EUnetHTA 21 Transversal Deliverables

Deliverables	Start Public consultation
D7.1 Guidance for the interaction between HTA experts and health technology developers (HTD) during JCA and JSC	20-07-2022
D7.2.1 Guidance for consulting patients, clinical experts and other experts during JCA and JSC	01-08-2022
D7.3 Expert input templates	01-08-2022
D7.4 Workplan for Interaction with Regulators of medicinal products and of medical devices (section 7.4)	Published
D7.5 Guidance for identifying and handling conflict of interest (COI), declaration of interest and confidentiality agreement form	Published

4. Content

Anne Willemsen, ZIN Maggie Galbraith, HAS



4a. D7.1 HTD interaction

Anne Willemsen, ZIN



Upcoming public consultation

The deliverable D7.1 on interaction between HTD and HTA will go for public consultation between

July 20 and August 19, 2022

Consists of 3 sub-deliverables:

- D7.1.1 practical guideline for interaction between HTD and HTA
- D7.1.2 process for a factual accuracy check
- D7.1.3 process for confidential data

Please note, in EUnetHTA 21 some procedures may look different then under the HTA Regulation. This is pointed out in the sub-deliverable when relevant



HTA Regulation articles

The sub-deliverables are based on:

- the requirements laid down in the HTA Regulation;
- as well as experiences from Joint Action 3 and;
- recommendations expressed in the FMC work.



D7.1.1 – Practical Guideline for interaction between HTD and HTA

- It defines the role of HTA bodies, Secretariat and Health Technology Developer (HTD) in JCA and JSC procedures
- It defines the process steps for the JSC and JCA procedures
- Time points for interaction and the objective thereof, before during and after the procedure. E.g:
 - For JSC:
 - Application and selection of a JSC, submission of briefing book, list of issues, the F2F meeting, final recommendations and evaluation
 - For JCA:
 - Selection of a technology, submission of PICO to HTD, submission of a dossier and the check for completeness, publication of a JCA and evaluation procedure (under EUnetHTA 21)



D7.1.2 – Process for factual accuracy check by HTD

- Defines the time points and process for the factual accuracy check by a HTD for a JCA process
 - Notification of the process, sharing of the draft JCA report for the factual accuracy check, collecting the comments from HTD and providing answers to the HTD comments
- It holds a checklist on what can be reviewed by the HTD



D7.1.3 – Process for handling of commercial and academic in-confidence data

- Defines the concept of commercially in-confidence data and personal data for both JSC and JCA
 - It stipulates what information can and cannot be shared externally
- Defines the process for marking data confidential and what happens
- Explains why academic in-confidence is not accepted for JSC and JCA purposes



4b. D7.2/7.3 Patient/HCP

Maggie Galbraith, HAS



Upcoming public consultation

Deliverables 7.2/7.3 – Involvement of Patients, Healthcare Professionals, and other experts will go for public consultation between August 1 and August 30, 2022

- D7.2 Guidance for involvement of patients and clinical experts in JCA and JSC
- D7.3 Template for patient input and template for HCP input which consists of 3 questionnaires:
 - 1 Patient stakeholder
 - Patient expert 2.
 - 3. Clinical expert



EUnetHTA 21 -Assessments (JCA)


Health Technology Assessment (HTA) on <health technology> for

EUnetHTA 21 - India Clinical Assessments (JCA) and Joint Scientific Consultations (JSC) Health Technology Assessment (HTA) or Scientific Consultation or

Introduction

a that cali

- prior completion of a declaration of inte SCA) is required. After clearance by the El
- ehris grou How to complete this template
- - speciences at different stages of the condition



sent or Joint Scientific Consultation on shealth tech

input relating to medical devices. Questions can therefore be adapted where n

is termilate can be used by the (col-Assessor as a disc In a complete can be used by one conversion as a discussion golde on your interview or it can be completed by you as a written statement. If used as a discussion guide, your interview will be summarised by the (co)-Assessor and you will have the opportunity to review and validate the summary before your input will be used. If you complete the template as a written ement please provide details of references or sources for your input where necessary (e.g. n referencing specific guidelines or studies).



Objectives and General Principles D7.2/3

Objectives are to develop:

- Guidance for the interaction with and involvement of external experts (patient experts and clinical experts) and patient representatives in JSC and JCA
- A template for patient expert /patient representative input into JSC and JCA.
- A template for clinical expert input into JSC and JCA.

General Principles:

- Early engagement
 - Stakeholders via open call at the very beginning of the JCA process
 - Experts beginning with PICO consolidation (JCA)/List of Issues (JSC)
- Sharing of information with experts based on needs of Assessor/ coAssessor and the expert's skillset
- Summary of input validated by the experts



D7.2 Subjects Addressed in Guidance

- Distinction between stakeholders and experts
- Recruitment of stakeholders and experts
- Confidentiality and conflict of interest
- Creation of a EUnetHTA 21 expert database (patient and clinician)
- Timepoints and methods for involving clinicians and patients
- Reporting on expert involvement in the JSC Recommendations or JCA Report
- Naming of experts
 - Clinical experts to be named if they want
 - Patient experts not to be named and identifying information not to be published
- Considerations for the future (HTAR)
 - Need to expand guidance to cover other types of experts and consumers
 - Adaptations needed for medical devices



Patient and Clinician Involvement in JCA

	-				
Timepoint	Purpose	Туре	Level	Method(s)	Information shared
Before National PICO	Obtain information on living with the disease; expectations of new treatment etc. This information is obtained well in advance before the JCA scoping starts, so that HTA bodies who do not have a national procedure in place to involve patients can still benefit from patient input.	stakeholder	European	(online) questionnaire	Indication and the questionnaire
Input during PICO development (National level – methods depend on the national procedures in place)	Obtain information on living with the disease; expectations of new treatment etc; Assist in defining national PICO	External experts and/or stakeholders (depends on the national procedure)	National	National procedures	As per national requirement
PICO consolidation, during scoping process	Patient and clinical expert input is used to support defining national PICO and as a validation tool for the consolidated PICO(s).	External experts	European	Including patient and clinical expert input templates, Interviews and meeting participation (as per guideline)	Details of indication under review. This is done early in scoping phase so no draft PICO available
Draft JCA report	Answer specific questions from the Assessor/Co-Assessor	External experts	European	ad-hoc questions, interviews if necessary	Depends on mode of involvement, but could be draft JCA report or specific information needed to understand the context of a question



Patient and Clinician Involvement in JSC

		-	-	-	
Timepoint	Purpose	Туре	Level	Method(s)	Information shared
Approach 1 Prior to draft written recommendations	Obtain information on living with the disease; expectations of new treatment etc; getting input following the PICO scheme	External experts	National, generally	Approach 1: Interview (or written statement) based on questionnaire	No documents are shared
Approach 2 Prior to draft written recommendations		External experts	National, generally	Approach 2: Approach 1 + Respond to specific questions re: HTD development plan	Providing the briefing package or relevant sections of the briefing package when a specific contribution is required
Approach 3 Prior to draft List of Issues		External experts	European	Approach 3: Approach 2 + Review draft List of Issues and participate in meeting with EMA and HTD	



D7.3 Subjects Addressed in Questionnaires

For Patients

• Developed Based on HTAi questionnaire and JA3



D7.2/D7.3 Timelines

Task	Date
HOG began work	14/03/2022
First CSCQ Consensus Meeting	17/05/2022
Patient and clinical expert round table	25/05/2022
Second CSCQ Consensus Meeting	13/07/2022
Multi-stakeholder meeting	13/07/2022
Public Consultation	01/08/2022- 31/08/2022
Expected Publication Date	04/11/2022



Thank you!





5. JCA pilot

Chantal Guilhaume, HAS Anne Willemsen, ZIN



Objectives JCA production in EUnetHTA 21

Continue to improve quality, consistency and uptake of JCA

- Further standardize production process in line with HTA R articles
- Pilot work developed during EUnetHTA 21
 - Practical guidelines, procedure and templates
 - Evaluate and adjust based on experiences
- Refine interaction in line with the HTA Regulation
 - CSCQ review/validation and CEB endorsement
- Explore interaction with stakeholders
 - Health Technology Developer (HTD), patients, clinical experts and regulators
- Identify potential changes to national systems to use JCA



Consolidated PICO at the center of the JCA

Direct consequences:

- Inclusive scope
 - All requests from MS need to be included
 - Assessment teams might have to answer more questions than in a national process (more work)
 - MS using the assessment need to extract the relevant information from the JCA for further use in national assessment and appraisal
- The PICO format will be used to request data requirements from HTD and for MS to inform the assessment scope

Indirect consequences:

- A process equivalent to a PICO survey required to collect MS scope
- > No separate PICO's per MS, but consolidated form to minimalize overlap



Submission dossier guidance

Submission dossier guidance document

Currently under public consultation Submission dossier template

Appendix: Table templates



EUnetHTA 21 JCA production timelines Medicinal Products JCA

- Timelines are dependent on regulatory assessment timeline
 - Eligible products: initial marketing authorisation

Milestone	Month	
Letter of Intent	August, 2022	
Consolidated PICO	26 October, 2022	
Submission Dossier	9 January, 2023 45 days before CHMP opinion, as per HTA Regulation	
CHMP opinion	February, 2023 Last CHMP meeting day=23 Feb	
Publication JCA report	31 May, 2023 Allowing 4-5 months for EUnetHTA21 to revise and update their deliverables before closing in September 2023	

*timelines for earlier or later start can be discussed bilaterally



Who will be the EUnetHTA 21 JCA team?

Assessor & co-assessor

- HAS (France) & INFARMED (Portugal)

JCA coordination

- ZIN (Netherlands)


EUnetHTA 21 joint report

- All **CSCQ members** will be involved throughout the production and act as reviewers
- In total, 12 countries

Further inclusion of HTA perspective by

- Non-consortium HTAb from EU/EEA countries





EUnetHTA 21 JCA production, selection & timelines *Medical Devices JCA*

- Focus on high risk MD (class IIb, III)
 - With or without expert panel opinion
- Not many time constraints based on HTA Regulation
 - No publication deadline given
 - Important to consider no parallel assessment on EU and national level
 - Submission dossier should include information from scientific opinion

To avoid duplication between regulatory and HTA submission dossier

Milestone	Month
Letter of Intent	August/September, 2022
Consolidated PICO	October, 2022
Submission Dossier	December, 2022 - January, 2023
Publication JCA report	May, 2023



Who will be the EUnetHTA 21 JCA team?

Assessor & co-assessor

- HAS (France) & AIHTA (Austria)

JCA coordination

- ZIN (Netherlands)

EUnetHTA 21 joint report

- All **CSCQ members** will be involved throughout the production and act as reviewers
- In total, 12 countries

Further inclusion of HTA perspective by

- Non-consortium HTAb from EU/EEA countries



Next steps



Next steps

- Please reach out to <u>JCA_Secretariat@zinl.nl</u> if you are interested in a JCA for medicinal products or medical devices
 - Submit Letter of Intent by August the latest
 - We will proceed with a call to explain the procedure
- For HTD who submitted a Letter of Intent
 - PICO information meeting: we explain the consolidated PICO
 - Exchange on submission dossier template
 - Factual Accuracy Check of the final draft JCA report
 - Evaluation of the JCA procedure



Public Consultations

Anne Willemsen, ZIN



Ongoing & Anticipated Public Consultations

https://www.eunethta.eu/jointhtawork/

Status	Deadline	Deliverable	Title
Closed	March 7 – April 5, 2022	D5.3.1	Selection criteria (co-)assessor JCA
	May 20, 2022, EOB	D5.3.2	HTA body technical expert working groups
	May 2 – May 31, 2022	D4.2	Practical Guideline – Scoping Process
		D4.7.1, 4.7.2	Framework for JCA of high risk MD
		D4.3.2	Methodological Guideline – Direct & Indirect Comparators and Comparisons
	June 6 – July 7, 2022	D4.7.3, 4.7.4	EUDAMED data reporting template/Guidance for EUDAMED-based TISP process
Ongoing	July 4 – Aug 2, 2022	D5.1	Submission Dossier Template (guidance)
		D4.5	Applicability of Evidence
		D4.6	Validity of Clinical Studies
	July 20 – Aug 19, 2022	D7.1	HTD and HTA interaction
Announced	Aug 1 – Aug 30, 2022	D5.2	JCA report template
		D7.2/7.3	Patient and HCP guidance & templates for interaction
		4.3.1	Comparators and comparisons
Diappod	Oct 3 – Nov 1, 2022	D4.4	Endpoints
Planned	Aug 1 – Aug 31, 2023	D6.2/6.3 & 6.4	JSC briefing book template & procedural guidance



6. **Q&A**

Niklas Hedberg, TLV



7. Closing remarks

Niklas Hedberg, TLV

